PARAMOUNT trial
Clinical trial studying non-small-cell lung carcinoma / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about PARAMOUNT trial?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly and Company and was conducted in several European countries and Canada. It was registered in November 2008 and was projected to end in September 2013.
Quick Facts other names, sponsor ...
other names | PARAMOUNT, NCT00789373 |
---|---|
sponsor | Eli Lilly and Company |
number of participants | 939 |
start | November 2008 |
end | September 2013 |
primary completion | June 2010 |
Close
PARAMOUNT found that maintenance therapy with pemetrexed for patients with advanced non-squamous NSCLC was an effective and well-tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus cisplatin.